Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Recruiting now · Not applicable

Conditions studied: Unresectable Hepatocellular Carcinoma (HCC)

In brief

The goal of this interventional study is to compare treatment response between transarterial chemoembolization (TACE) combined with lenvatinib and lenvatinib monotherapy in patients with unresectable hepatocellular carcinoma. The study aims to determine whether the addition of TACE to lenvatinib results in improved tumor response compared with lenvatinib alone in a real-world clinical setting.

Key facts

Study ID

NCT07408804

Run by

Bangladesh Medical University

People needed

40

Starts

2025-04-08

Expected to finish

2026-09-30

Last updated by the study team

2026-02-13

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-75 years,
• Hepatocellular carcinoma, confirmed by dynamic CT scan / MRI or histopathology, consistent with early (stage A), Intermediate (Stage B), subgroup B, and Advanced (stage C) according to BCLC criteria 2022, without a history of any previous treatment,
• At least one measurable lesion based on mRECIST criteria,
• ECOG performance status 0-2,

You may not qualify if…

• Diffuse bi-lobar or multi nodular HCC (more than 10 nodules) with more than equal 50% liver involvement,
• Hepatocellular carcinoma with main trunk portal vein thrombosis,
• Child Turcotte Pugh Score 10 ( C) or more,
• ALBI grade 3,
• Hepatocellular carcinoma with uncontrolled hypertension, recent myocardial infarction, or other thromboembolic event,
• Known allergy or intolerance to lenvatinib .

Where it is running

• Department of Hepatology, Bangladesh Medical University — Dhaka, Bangladesh (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.